Abstract
A series of novel derivatives of 1,3-oxazolidin-2-one 12a-12n has been synthesized starting from 4-nitro-(L)- phenylalanine by involving five-step reaction sequence. All the compounds were screened for their in vitro antibacterial activity against four pathogenic bacterial strains namely, Staphylococcus aureus, Bacillus subtilis (Gram-positive), Escherichia coli, Pseudomonas aeruginosa (Gram-negative) and in vitro antifungal activity against two pathogenic fungal strains namely, Candida albicans and Saccharomyces cerevisiae. All the synthesized compounds showed activity against Gram-positive bacteria. Compounds 12c and 12l exhibited maximum antibacterial activity against Gram-positive bacteria. However, against Gram-negative bacteria only five of screened compounds were found to be active. Compounds 12c and 12i displayed best antifungal activity against the tested fungi. Docking studies were carried out in order to gain insight into the mechanism of action and the binding mode of these compounds. These studies were in agreement with the biological data.
Keywords: 1, 3-Oxazolidin-2-one, Azomethine, Antibacterial activity, Antifungal activity, Docking study.
Current Topics in Medicinal Chemistry
Title:Design, Synthesis and Antimicrobial Evaluation of Novel 1,3-Oxazolidin-2- one Derivatives
Volume: 13 Issue: 16
Author(s): Nisha Chandna, Jitander K. Kapoor, Varsha Goyal, Neeraj K. Aggarwal, Kotni Meena Kumari and Manga Vijjulatha
Affiliation:
Keywords: 1, 3-Oxazolidin-2-one, Azomethine, Antibacterial activity, Antifungal activity, Docking study.
Abstract: A series of novel derivatives of 1,3-oxazolidin-2-one 12a-12n has been synthesized starting from 4-nitro-(L)- phenylalanine by involving five-step reaction sequence. All the compounds were screened for their in vitro antibacterial activity against four pathogenic bacterial strains namely, Staphylococcus aureus, Bacillus subtilis (Gram-positive), Escherichia coli, Pseudomonas aeruginosa (Gram-negative) and in vitro antifungal activity against two pathogenic fungal strains namely, Candida albicans and Saccharomyces cerevisiae. All the synthesized compounds showed activity against Gram-positive bacteria. Compounds 12c and 12l exhibited maximum antibacterial activity against Gram-positive bacteria. However, against Gram-negative bacteria only five of screened compounds were found to be active. Compounds 12c and 12i displayed best antifungal activity against the tested fungi. Docking studies were carried out in order to gain insight into the mechanism of action and the binding mode of these compounds. These studies were in agreement with the biological data.
Export Options
About this article
Cite this article as:
Chandna Nisha, Kapoor K. Jitander, Goyal Varsha, Aggarwal K. Neeraj, Kumari Meena Kotni and Vijjulatha Manga, Design, Synthesis and Antimicrobial Evaluation of Novel 1,3-Oxazolidin-2- one Derivatives, Current Topics in Medicinal Chemistry 2013; 13 (16) . https://dx.doi.org/10.2174/15680266113139990132
DOI https://dx.doi.org/10.2174/15680266113139990132 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lectin Microarrays: A Powerful Tool for Glycan-Based Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Editorial [Hot Topic: New Strategy for Drug Discovery Using Monoclonal Antibody (Guest Editor: Yukihiro Shoyama)]
Current Drug Discovery Technologies Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Meet the Editorial Board
Current Cancer Drug Targets Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Editorial (Thematic Issue: Study and Prediction of Pharmacokinetic Drug-Drug Interactions)
Current Drug Metabolism Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus
Current Proteomics Editorial (Thematic Issue: Emerging Concepts and Therapeutics Strategies for the Treatment of Brain Tumors)
Anti-Cancer Agents in Medicinal Chemistry The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Key microRNAs Regulated the Development of Non-small Cell Lung Cancer by Targeting TGF-β-induced epithelial–mesenchymal Transition
Combinatorial Chemistry & High Throughput Screening High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design